-
2 weeks ago | 
advancingrna.com | Anna Welch |Advancing RNA |Erin Harris
Is The mRNA Payload The Real MVP Of Targeted Delivery? As one delightfully colorful quote from a panel discussion at the AMM Ascent meeting last fall reminds us, there’s a lot more to be explored, discussed, and understood as it relates to the mRNA cargo’s role in targeted delivery.
-
Jan 13, 2025 | 
advancingrna.com | Anna Welch |Advancing RNA
By Anna Rose Welch, Editorial & Community Director, Advancing RNA
At the end of every year, I sit down with several mRNA/RNA C-suite executives to take stock of the previous year and to discuss predictions for what is yet to come. For those of you who have been following my columns, you’ll know that this year’s interviews turned into a two-part Q&A series that channeled a few ghosts — the Charles Dickens ghosts of mRNA’s past/present and the ghosts of mRNA’s future, to be specific.
-
Dec 22, 2024 | 
parergon.org | Anna Welch
Abstract Embroidered bindings were an important aspect of the culture of luxury goods associated with the Stuart court, and several surviving examples are associated with Charles’ queen Henrietta Maria, including one in the John Emmerson Collection, State Library Victoria, Melbourne, Australia.
-
Nov 26, 2024 | 
advancingrna.com | Anna Welch |Advancing RNA
By Anna Rose Welch, Editorial & Community Director, Advancing RNA
Over the past few months, I’ve been publishing articles centered on a topic that certainly seems miles and miles down the road for the RNA therapeutics space: Commercialization. However, having spent a few years in the biosimilar space, as well as the cell & gene therapy space prior to the mRNA world, I’ve become increasingly sensitive to the ways history tends to repeat itself across modalities.
-
Nov 23, 2024 | 
advancingrna.com | Anna Welch |Advancing RNA
By Anna Rose Welch, Editorial & Community Director, Advancing RNA
In this industry, we love to group our biggest challenges into threes:
Education, education, education.
Quality, quality, quality.
Delivery, delivery, delivery.
Such repetition is certainly warranted, given the importance of each of these terms in the RNA space.
-
Nov 4, 2024 | 
advancingrna.com | Anna Welch |Advancing RNA
By Anna Rose Welch, Editorial & Community Director, Advancing RNA
As I’ve prefaced in a handful of articles, there are many reasons we’re simultaneously living in “the best of times and the worst of times” in the ATMP space. To be sure, the financial landscape is improving day by day, and we continue to see more clinical advancements, positive data, and regulatory approvals.
-
Oct 25, 2024 | 
advancingrna.com | Anna Welch |Advancing RNA
By Anna Rose Welch, Editorial & Community Director, Advancing RNA
“It was the best of times, it was the worst of times…”
I dare say most of us have heard (or used) this A Tale of Two Cities quote by Charles Dickens in a manner of situations — and now, the time has come to apply it to the ATMP space.
-
Oct 18, 2024 | 
advancingrna.com | Anna Welch |Advancing RNA
By Anna Rose Welch, Editorial & Community Director, Advancing RNA
“We’re building the plane as we’re flying it.”
It’s a phrase we’ve relied upon heavily the last few years as we’ve strived to bring cell and gene therapies into/through the clinic while also establishing new technologies, manufacturing platforms, and a regulatory paradigm.
I was thinking about this phrase once more as I collected my thoughts following Cytiva’s recent RNA-LNP virtual summit.
-
Oct 11, 2024 | 
advancingrna.com | Anna Welch |Advancing RNA
By Anna Rose Welch, Editorial & Community Director, Advancing RNA
Over the past few weeks, I’ve spent what seems like an inordinate amount of time focusing on regulatory matters spurring discussion in the mRNA space today. And this article will be no exception.
I recently attended a panel discussion during an RNA-LNP virtual summit hosted by Cytiva.
-
Sep 30, 2024 | 
advancingrna.com | Anna Welch |Advancing RNA
By Anna Rose Welch, Editorial & Community Director, Advancing RNA
There are a lot of impressive development and regulatory milestones we can celebrate about mRNA’s meteoric rise to fame. But I never cease to be struck by one seemingly simple way the mRNA industry continues to flaunt development norms.
